GeoVax Labs, an innovative biotechnology company currently developing vaccines in order to prevent and treat HIV/AIDS, announced earlier today the appointment of Arban Domi, Ph.D., as its Director, Vector Development.
Dr. Domi will not only be an influential player in the continued development of GeoVax’s HIV vaccines, of which are now being evaluated in human clinical trials, but also in the development of versions of the company’s vaccines for the subtypes of HIV affecting the developing world. In addition, Dr. Domi’s expertise will be instrumental in the company’s evaluation of the suitability of vaccine constructs for commercial-scale vaccine manufacturing processes. GeoVax’s vaccines, in various combinations and doses, have been tested in close to 500 humans.
Dr. Domi earned his Ph.D. from the University of Paris and received his postdoctoral training at the Jacques Monod Institute of Molecular Biology in Paris. In both his thesis and postdoctoral studies he intelligently addressed the replication of the vaccinia virus and the construction of cell lines for use in vaccine production. From August 2000 to August 2008 he was a Research Fellow in the Laboratory of GeoVax collaborator, Dr. Bernard Moss, at the U.S. National Institutes of Health, where he pursued his research on poxviruses, viral vectors and recombinant virus construction as well as in the replication and egress of the vaccinia virus. Dr. Domi was also the co-inventor of the first infectious clone of a poxvirus cloned in bacteria and implemented a new expression system, VAC-BAC shuttle vector system for the construction of recombinant poxviruses in E. Coli. He joined the International AIDS Vaccine Initiative (IAVI) laboratory in Brooklyn, New York in 2008, as a Principal Scientist and since 2011 he has been the head of Process Development and Virus Production at IAVI.
“We are very pleased that Dr. Domi will be joining us,” stated GeoVax’s Chief Scientific Officer, Harriet Robinson. “Arban’s expertise in working with vaccinia virus and constructing recombinant viruses, as well as his experience as a Principal Scientist at the International AIDS Vaccine Initiative, will greatly add to our scientific talent at GeoVax. We are fortunate that our vaccine program could attract a professional of Dr. Domi’s caliber, and we look forward to his contributions.”
For more information, please visit www.geovax.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment